Experimental Study on Early Diagnosis of Malignant Pleural Mesothelioma with Computed Tomography Combined Serum Soluble Mesothelin-Related Proteins

被引:0
|
作者
Jiang Jie [1 ]
Qin Zhanxiong [2 ]
Wu Li [1 ]
Xie Xiaojie [1 ]
Zhao Xunran [1 ]
Zhao Wen [1 ]
Han Dan [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Med Imaging, Kunming 650032, Yunnan, Peoples R China
[2] Kunming City Maternal & Child Hlth Hosp, Radiol Dept, Kunming 650031, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
Computed Tomography; Mesothelium; Malignant Pleural Mesothelioma; Serum Soluble Mesothelin-Related Proteins; PROGNOSTIC VALUE; PEPTIDES;
D O I
10.1166/jmihi.2021.3314
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To investigate the value on early diagnosis of experimental rat according to computed tomography (CT) combined with the serum level of Serum Soluble Mesothelin-related Proteins (SMRP). Methods: Thirty-two SD rat were divided into three groups, including group A (experimental group) of 20 rats with pleural cavity injection of crocidolite suspension, group B (negative control group) of 6 rats with pleural cavity injection of saline, group C (blank control group) of 6 rats without any processing. Chest and abdominal CT scan and enhancement were performed in the three months and six months after induction and the pleural thickening was analyzed. The serum level of SMRP was measured at the different time period including pre-injection, the post-injection first month, the second month, the third month and the sixth month. The correlation between pleural thickening and serum level of SMRP was analyzed. Results: In group A: 20 cases were performed on CT scan in post-injection third month and we found 13 cases without pleural lesions and 7 cases with pleural lesions including of 4 cases with mild pleural thickening, 1 moderate thickening and 2 severe thickening (2 cases died). Moreover, 18 cases were done by CT in post-injection third month and we found 3 cases without pleural lesions and 15 cases with pleural lesions including of 6 cases with mild pleural thickening, 5 moderate thickening and 4 severe thickening (3 cases died). No pleural lesions were found in group B and group C. SMRP expression level differences in the three groups was statistically significant. However, there was no difference in pre-injection in the three groups and there were no difference in group B and C at the different time period. In group A, there was no difference between post-injection first month and second month, whereas, there had statistically difference in post-injection third and sixth month. In group A, SMRP level gradually increased over time. The high correlation between pleural thickening and serum level of SMRP was seen at the post-injection third and sixth month, which the expression of SMRP gradually increased as the pleural thickening. Conclusion: Serum SMRP expression level has a certain value for early diagnosis and staging of MPM, which can be used as an important biomarker for early screening of high-risk groups exposed to asbestos.
引用
收藏
页码:667 / 671
页数:5
相关论文
共 50 条
  • [21] Soluble mesothelin-related protein (SMRP) is a useful biomarker for malignant mesothelioma in Japan
    Fukuoka, K.
    Uesaka, A.
    Kuribayashi, K.
    Miyake, M.
    Miyata, S.
    Nakajima, T.
    Iida, S.
    Nobuyama, S.
    Tamura, K.
    Yamada, S.
    Murakami, A.
    Nakano, T.
    LUNG CANCER, 2006, 54 : S38 - S39
  • [22] Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide
    Dipalma, Nicola
    Luisi, Vito
    Di Serio, Francesca
    Fontana, Antonietta
    Maggiolini, Piera
    Licchelli, Brunella
    Mera, Ernesto
    Bisceglia, Lucia
    Galise, Ida
    Loizzi, Michele
    Pizzigallo, Maria Annunziata
    Molinini, Raffaele
    Vimercati, Luigi
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2011, 26 (03): : 160 - 165
  • [23] Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
    Canessa, Pier Aldo
    Franceschini, Maria Cristiana
    Ferro, Paola
    Battolla, Enrico
    Dessanti, Paolo
    Manta, Carmen
    Sivori, Massimiliano
    Pezzi, Riccardo
    Fontana, Vincenzo
    Fedeli, Franco
    Pistillo, Maria Pia
    Roncella, Silvio
    CANCER INVESTIGATION, 2013, 31 (01) : 48 - 55
  • [24] Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy
    Mitra, Sonali
    Jang, Hee-Jin
    Kuncheria, Allen
    Kang, Sung Wook
    Choi, Jong Min
    Shim, Ji Seon
    Lee, Claire
    Ranchod, Priyanka
    Jindra, Peter
    Ramineni, Maheshwari
    Patel, Meera
    Ripley, R. Taylor
    Groth, Shawn S.
    Blackmon, Shanda H.
    Burt, Bryan M.
    Lee, Hyun-Sung
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (04):
  • [25] PERFORMANCE OF A COMBINATION OF SERUM BIOMARKERS, INCLUDING SOLUBLE MESOTHELIN-RELATED PEPTIDE (SMRP), IN DIAGNOSING MALIGNANT MESOTHELIOMA
    Okada, Asuka
    Fukuoka, Kazuya
    Yamada, Syusai
    Otsuki, Taiichiro
    Masachika, Eriko
    Kamiya, Hitomi
    Honda, Miki
    Okuwa, Hisaya
    Nogi, Yoshitaka
    Mikami, Kouji
    Maeda, Risa
    Tamura, Kuninobu
    Tabata, Chiharu
    Nakano, Takashi
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1051 - S1052
  • [26] Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
    Santarelli, Lory
    Strafella, Elisabetta
    Staffolani, Sara
    Amati, Monica
    Emanuelli, Monica
    Sartini, Davide
    Pozzi, Valentina
    Carbonari, Damiano
    Bracci, Massimo
    Pignotti, Elettra
    Mazzanti, Paola
    Sabbatini, Armando
    Ranaldi, Renzo
    Gasparini, Stefano
    Neuzil, Jiri
    Tomasetti, Marco
    PLOS ONE, 2011, 6 (04):
  • [27] Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis
    Luo, Ling
    Shi, Huan-Zhong
    Liang, Qiu-Li
    Jiang, Jing
    Qin, Shou-Ming
    Deng, Jing-Min
    RESPIRATORY MEDICINE, 2010, 104 (01) : 149 - 156
  • [28] Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma
    Ashour, Wafaa M.
    Amin, Hassan
    Sabri, Irin M.
    Samir, Aisha M.
    Zaki, Dalia A. H.
    Fathy, Mona M.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2012, 61 (03): : 121 - 128
  • [29] Detection of Soluble Mesothelin in Serum and Pleural Effusion of Malignant Pleural Mesothelioma: A Contribution to Cytology
    Fedeli, F.
    Canessa, P. A.
    Ferro, P.
    Battolla, E.
    Dessanti, P.
    Vigani, A.
    Chiaffi, L.
    Franceschini, M. C.
    Fontana, V.
    Bacigalupo, B.
    Pistillo, M. P.
    Roncella, S.
    LABORATORY INVESTIGATION, 2013, 93 : 452A - 452A
  • [30] SOLUBLE MESOTHELIN RELATED PROTEIN (SMRP) IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Azim, H. A., Jr.
    Gaafar, R.
    Abdelsalam, I.
    Khorshid, O.
    Elguindi, S.
    Elattar, I.
    Ashmawy, A.
    LUNG CANCER, 2009, 64 : S66 - S66